Activation of Phosphatidylinositol 3-kinase/protein Kinase B by Corticotropin-releasing Factor in Human Monocytes

Overview

Journal Endocrinology

Publisher Oxford University Press

Specialty Endocrinology

Date 2009 Jul 25

PMID 19628576

Citations 7

Authors

Christina Chandras

Yassemi Koutmani

Efi Kokkotou

Charalabos Pothoulakis

Katia P Karalis

Affiliations

Soon will be listed here.

Abstract

Corticotropin-releasing factor (CRF) exerts proinflammatory effects in peripheral tissues, whereas the intracellular pathways mediating these effects have not been completely characterized yet. We have previously shown that CRF induces nuclear factor-kappaB DNA-binding activity in mouse and human leukocytes. Here we demonstrate that in the human monocytic THP-1 cells, CRF activates the phosphatidylinositol 3-kinase (PI3K)/Akt and ERK1/2 pathways. These effects of CRF are mediated by corticotropin-releasing factor receptor 2 (CRF2), as suggested by their abolishment after treatment with the specific CRF2 antagonist, astressin 2B. The CRF-mediated PI3K/Akt activation induces cell survival as suggested by the stimulation of the antiapoptotic factor Bcl-2. ERK1/2 activation results in up-regulation of IL-8 expression, an effect inhibited by the CRF-induced activation of PI3K/Akt. These studies demonstrate novel effects of CRF in human monocytes mediated by the activation of PI3K/Akt. Moreover, they reveal pathway-specific effects of the CRF/CRF2 system in chemokine activation and cell survival that may be of importance for the development of novel therapeutics for inflammatory diseases.

Citing Articles

Urocortin stimulates the ERK1/2 signaling pathway and the proliferation of HeLa cells via CRF receptor 1.

Balogh B, Vecsernyes M, Stayer-Harci A, Berta G, Tarjanyi O, Setalo Jr G FEBS Open Bio. 2023; 13(5):818-832.

PMID: 36971048 PMC: 10153344. DOI: 10.1002/2211-5463.13602.

Corticotropin-Releasing Hormone: Biology and Therapeutic Opportunities.

Caruso A, Gaetano A, Scaccianoce S Biology (Basel). 2022; 11(12).

PMID: 36552294 PMC: 9775501. DOI: 10.3390/biology11121785.

Identification of a novel interaction between corticotropin releasing hormone (Crh) and macroautophagy.

Giannogonas P, Apostolou A, Manousopoulou A, Theocharis S, Macari S, Psarras S Sci Rep. 2016; 6:23342.

PMID: 26987580 PMC: 4796911. DOI: 10.1038/srep23342.

Corticotropin-Releasing Hormone Receptor 2 Signaling Promotes Mucosal Repair Responses after Colitis.

Hoffman J, Baritaki S, Ruiz J, Sideri A, Pothoulakis C Am J Pathol. 2015; 186(1):134-44.

PMID: 26597886 PMC: 4714033. DOI: 10.1016/j.ajpath.2015.09.013.

Corticotropin-releasing Factor Changes the Phenotype and Function of Dendritic Cells in Mouse Mesenteric Lymph Nodes.

Meng L, Lu Z, Xiaoteng W, Yue H, Bin L, Lina M J Neurogastroenterol Motil. 2015; 21(4):571-80.

PMID: 26424042 PMC: 4622140. DOI: 10.5056/jnm15019.

References

Kishimoto T, Pearse 2nd R, Lin C, Rosenfeld M . A sauvagine/corticotropin-releasing factor receptor expressed in heart and skeletal muscle. Proc Natl Acad Sci U S A. 1995; 92(4):1108-12. PMC: 42647. DOI: 10.1073/pnas.92.4.1108. View

Grigoriadis D, Liu X, Vaughn J, Palmer S, True C, Vale W . 125I-Tyro-sauvagine: a novel high affinity radioligand for the pharmacological and biochemical study of human corticotropin-releasing factor 2 alpha receptors. Mol Pharmacol. 1996; 50(3):679-86. View

Liaw C, Lovenberg T, Barry G, Oltersdorf T, Grigoriadis D, DE SOUZA E . Cloning and characterization of the human corticotropin-releasing factor-2 receptor complementary deoxyribonucleic acid. Endocrinology. 1996; 137(1):72-7. DOI: 10.1210/endo.137.1.8536644. View

Karalis K, Muglia L, Bae D, Hilderbrand H, Majzoub J . CRH and the immune system. J Neuroimmunol. 1997; 72(2):131-6. DOI: 10.1016/s0165-5728(96)00178-6. View

Fukao T, Tanabe M, Terauchi Y, Ota T, Matsuda S, Asano T . PI3K-mediated negative feedback regulation of IL-12 production in DCs. Nat Immunol. 2002; 3(9):875-81. DOI: 10.1038/ni825. View

Brar B, Stephanou A, Knight R, Latchman D . Activation of protein kinase B/Akt by urocortin is essential for its ability to protect cardiac cells against hypoxia/reoxygenation-induced cell death. J Mol Cell Cardiol. 2002; 34(4):483-92. DOI: 10.1006/jmcc.2002.1529. View

Crofford L, Sano H, Karalis K, Webster E, Goldmuntz E, Chrousos G . Local secretion of corticotropin-releasing hormone in the joints of Lewis rats with inflammatory arthritis. J Clin Invest. 1992; 90(6):2555-64. PMC: 443415. DOI: 10.1172/JCI116150. View

Guha M, Mackman N . The phosphatidylinositol 3-kinase-Akt pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human monocytic cells. J Biol Chem. 2002; 277(35):32124-32. DOI: 10.1074/jbc.M203298200. View

Parsa K, Ganesan L, Rajaram M, Gavrilin M, Balagopal A, Mohapatra N . Macrophage pro-inflammatory response to Francisella novicida infection is regulated by SHIP. PLoS Pathog. 2006; 2(7):e71. PMC: 1513262. DOI: 10.1371/journal.ppat.0020071. View

10.

Tsatsanis C, Androulidaki A, Dermitzaki E, Charalampopoulos I, Spiess J, Gravanis A . Urocortin 1 and Urocortin 2 induce macrophage apoptosis via CRFR2. FEBS Lett. 2005; 579(20):4259-64. DOI: 10.1016/j.febslet.2005.06.057. View

11.

Marte B, Downward J . PKB/Akt: connecting phosphoinositide 3-kinase to cell survival and beyond. Trends Biochem Sci. 1997; 22(9):355-8. DOI: 10.1016/s0968-0004(97)01097-9. View

12.

Takahashi M, Matsui A, Inao M, Mochida S, Fujiwara K . ERK/MAPK-dependent PI3K/Akt phosphorylation through VEGFR-1 after VEGF stimulation in activated hepatic stellate cells. Hepatol Res. 2003; 26(3):232-236. DOI: 10.1016/s1386-6346(03)00112-8. View

13.

Lezoualch F, Engert S, Berning B, Behl C . Corticotropin-releasing hormone-mediated neuroprotection against oxidative stress is associated with the increased release of non-amyloidogenic amyloid beta precursor protein and with the suppression of nuclear factor-kappaB. Mol Endocrinol. 2000; 14(1):147-59. DOI: 10.1210/mend.14.1.0403. View

14.

Crofford L, Sano H, Karalis K, Friedman T, Epps H, Remmers E . Corticotropin-releasing hormone in synovial fluids and tissues of patients with rheumatoid arthritis and osteoarthritis. J Immunol. 1993; 151(3):1587-96. View

15.

Webster E, Lewis D, Torpy D, Zachman E, Rice K, Chrousos G . In vivo and in vitro characterization of antalarmin, a nonpeptide corticotropin-releasing hormone (CRH) receptor antagonist: suppression of pituitary ACTH release and peripheral inflammation. Endocrinology. 1996; 137(12):5747-50. DOI: 10.1210/endo.137.12.8940412. View

16.

Perrin M, Donaldson C, Chen R, Blount A, Berggren T, Bilezikjian L . Identification of a second corticotropin-releasing factor receptor gene and characterization of a cDNA expressed in heart. Proc Natl Acad Sci U S A. 1995; 92(7):2969-73. PMC: 42340. DOI: 10.1073/pnas.92.7.2969. View

17.

Lee J, Ye J, Gao Z, Youn H, Lee W, Zhao L . Reciprocal modulation of Toll-like receptor-4 signaling pathways involving MyD88 and phosphatidylinositol 3-kinase/AKT by saturated and polyunsaturated fatty acids. J Biol Chem. 2003; 278(39):37041-51. DOI: 10.1074/jbc.M305213200. View

18.

Strassheim D, Asehnoune K, Park J, Kim J, He Q, Richter D . Phosphoinositide 3-kinase and Akt occupy central roles in inflammatory responses of Toll-like receptor 2-stimulated neutrophils. J Immunol. 2004; 172(9):5727-33. DOI: 10.4049/jimmunol.172.9.5727. View

19.

Brar B, Jonassen A, Egorina E, Chen A, Negro A, Perrin M . Urocortin-II and urocortin-III are cardioprotective against ischemia reperfusion injury: an essential endogenous cardioprotective role for corticotropin releasing factor receptor type 2 in the murine heart. Endocrinology. 2003; 145(1):24-35; discussion 21-3. DOI: 10.1210/en.2003-0689. View

20.

Webster E, Torpy D, Elenkov I, Chrousos G . Corticotropin-releasing hormone and inflammation. Ann N Y Acad Sci. 1998; 840:21-32. DOI: 10.1111/j.1749-6632.1998.tb09545.x. View